Intravitreal bevacizumab injection for chronic central serous chorioretinopathy

Chinese Medical Journal

Volumn 123, Issue 15, 2010, Pages 2145-2147

  Li, Xiu Juan ^a   Zhang, Jin Song ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Central serous chorioretinopathy; Intravitreal bevacizumab; Retinal pigment epithelium detachment

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CASE REPORT; CENTRAL SCOTOMA; CENTRAL SEROUS RETINOPATHY; DRUG EFFICACY; FLUORESCENCE ANGIOGRAPHY; HUMAN; INFORMED CONSENT; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; RETINA PIGMENT EPITHELIOPATHY; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CENTRAL SEROUS CHORIORETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; MALE;

EID: 77956113230     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.15.035     Document Type: Article

References (13)

1. Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology 1989; 96: 854-859.
2. Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002; 22: 19-24.
3. Hussain D, Gass JD. Idiopathic central serous chorioretinopathy. Indian J Ophthalmol 1998; 46: 131-137.
4. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004; 137: 1073-1080.
5. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109: 1723-1725.
6. Bujarborua D, Chatterjee S, Choudhury A, Bori G, Sarma AK. Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina 2005; 25: 422-429.
7. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997; 104: 616-622.
8. Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003; 23: 235-237.
9. Colucciello M. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina 2006; 26: 239-242.
10. Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009; 53: 52-56.
11. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823.
12. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009; 54: 372-400.
13. Niegel MF, Schrage NF, Christmann S, Degenring RF. Intravitreal bevacizumab for chronic central serous chorioretinopathy. Ophthalmology 2008; 105: 943-945.